Podium to Practice: ASH® 2025 – LYMPHOMA: First Phase III Comparison of Non-Covalent vs. Covalent BTKi in CLL/SLL

Podium to Practice: ASH® 2025 – LYMPHOMA: First Phase III Comparison of Non-Covalent vs. Covalent BTKi in CLL/SLL

Podium to Practice: ASH® 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Carolyn Owen

Icon Chair Speaker

Speakers

Dr. Anca Prica

Dr. Kerry Savage

Studies / Trials Discussed

ID 683 – Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor

This program has been made possible through unrestricted support from Eli Lilly and Merck.

Studies/trials discussed:

ID 683 – Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor
Tagged